FDA Approvals, Dividends, New Technologies, and Solid Margins Increase Shareholder Value - Research Report on Abbott, Baxter,

    FDA Approvals, Dividends, New Technologies, and Solid Margins Increase
      Shareholder Value - Research Report on Abbott, Baxter, CareFusion,
                           Haemonetics, and CR Bard

PR Newswire

NEW YORK, August 1, 2013

NEW YORK, August 1, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Abbott
Laboratories (NYSE: ABT), Baxter International Inc. (NYSE: BAX), CareFusion
Corporation (NYSE: CFN), Haemonetics Corp. (NYSE: HAE), and CR Bard Inc.
(NYSE: BCR). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Abbott Laboratories Research Report

On July 25, 2013, Abbott Laboratories (Abbott) announced that its FreeStyle
Precision pro Blood Glucose and β-Ketone Monitoring System, which is an
advanced blood glucose monitoring system designed to address key needs of
hospital customers, has received US Food and Drug Administration (FDA)
clearance. Heather L. Mason, Senior Vice President, Diabetes Care at Abbott,
said, "The FreeStyle Precision Pro system represents a significant step
forward as we work to provide tools to improve the way hospitals manage
patients' glucose levels, It makes the data available in real time, thanks to
the meter's new wireless capabilities. With its individually foil-wrapped test
strips, the system is also designed to help reduce test strip
cross-contamination in hospital environments." The Full Research Report on
Abbott Laboratories - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-30/ABT]

--

Baxter International Inc. Research Report

On July 23, 2013, Baxter International Inc. (Baxter) announced that its Board
of Directors has approved a quarterly dividend of $0.49 per common share.
According to Baxter, the dividend is payable on October 1, 2013 to
shareholders of record as on September 6, 2013. Robert J. Hombach, CFO of
Baxter, said, "We remain committed to a disciplined capital allocation
strategy, balancing re-investment for growth with returning meaningful value
to our investors," Baxter also stated that it increased its dividend for
shareholders by 9% in May 2013, which came in after a 34% increase in the
dividend rate, which the Company implemented in 2012. The Full Research Report
on Baxter International Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-30/BAX]

--

CareFusion Corporation Research Report

On July 25, 2013, CareFusion Corp. (CareFusion) announced a partnership with
Our Lady of the Lake Regional Medical Center (Our Lady of the Lake). According
to CareFusion, the partnership aims for addition of new CareFusion's
technologies in Our Lady of the Lake hospital. The Company informed that these
new technologies will also improve medication safety by simplifying and
standardizing the medication management process. CareFusion also stated that
CareFusion Pyxis ES platform significantly reduces time for nursing and
pharmacy to dispense and administer medications because of simpler, more
efficient workflows. Rusty Frantz, Senior Vice President and General Manager
of Dispensing Technologies at CareFusion, said, "We look forward to
supporting Our Lady of the Lake with the most robust medication dispensing
solution available, the new Pyxis ES platform provides the next-generation of
technology to support safe medication dispensing and administration
efficiency." The Full Research Report on CareFusion Corporation - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-07-30/CFN]

--

Haemonetics Corp. Research Report

On July 29, 2013, Haemonetics Corp. (Haemonetics) announced its Q1 FY 2014
financial results (period ending 29, June, 2013) with net revenue of $219.5
million, up 24.4% YoY. Adjusted non-GAAP net income for the quarter totaled
approximately $23.8 million, up 46.3% YoY and adjusted non- GAAP diluted EPS
of $0.46, up 48.4% YoY. Brian Concannon, Haemonetics' President and CEO,
commented, "This quarter we made excellent progress advancing the
manufacturing transformation elements of our Value Creation & Capture (VCC)
initiatives. We are encouraged that, at the same time, we were able to drive a
270 basis point improvement in adjusted operating margin, enabling us to
deliver profit in line with our expectations and affirm our full year adjusted
earnings per share guidance range. This was achieved through productivity and
cost management efforts that will later be amplified by the full benefits of
the VCC initiatives." For full-year FY 2014, the Company anticipates total
revenue growth of 7% to 10% YoY. The Full Research Report on Haemonetics Corp.
- including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-30/HAE]

--

CR Bard Inc. Research Report

On July 23, 2013, CR Bard Inc. (CR Bard) announced that its Board of Directors
has approved a quarterly dividend of 49.5 cents per common share. The dividend
is payable on September 30, 2013 to shareholders of record as on September 9,
2013. The Company also stated that this dividend represents an annualized
dividend of $1.98 per share. The Full Research Report on CR Bard Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.investorsreports.com/report/2013-07-30/BCR]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

http://InvestorsReports.com



SOURCE Investors' Reports

Contact: Kristi Saunders, +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.